AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3425252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical scoring in accordance with Westin performed in weeks 24, 28 and 32 for groups I, II, and III
Number of subjects: 1327
Study 3425252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical scoring in accordance with Westin
Number of subjects: 1327
Study 3425252 — intervention group
Group type: COMPARATOR
Intervention: Cervical examination in low-risk pregnancies
Number of subjects: 1327
Study 29983095 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation during liver resection (group B, n = 39)
Number of subjects: 79
Study 29983095 — intervention group
Group type: COMPARATOR
Intervention: Liver resection without microwave ablation (group A, n = 40)
Number of subjects: 79
Study 28334979 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical medication reviews (CMR)
Number of subjects: 518
Study 28334979 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 518
Study 25440820 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (transgluteal)
Number of subjects: 98
Study 25440820 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 98
Study 23480528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 309
Study 23480528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 21181138 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype GG of rs4532
Number of subjects: 382
Study 21181138 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype CGC of rs5326-rs4532-rs265975
Number of subjects: 382
Study 18584240 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose TACE (2 mg mitomycin C, 10 mg epirubicin, 100 mg carboplatin)
Number of subjects: 54
Study 18584240 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose TACE (10 mg mitomycin C, 40 mg epirubicin, 300 mg carboplatin)
Number of subjects: 54
Study 18584240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TACE)
Number of subjects: 54
Study 17070365 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil
Number of subjects: 343
Study 17070365 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tadalafil
Number of subjects: 343
Study 17070365 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil
Number of subjects: 343
Study 17070365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 14560892 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for early-stage endometriosis
Number of subjects: 0
Study 14560892 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for moderate and severe endometriosis
Number of subjects: 0
Study 14560892 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment inducing an anovulatory state
Number of subjects: 0
Study 14560892 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted reproductive technologies (ART) including IVF
Number of subjects: 0
Study 14560892 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriomas impact on IVF outcome
Number of subjects: 0
Study 10964269 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor residual spraying with alphacypermethrin (Fendona) at 25 mg/m2
Number of subjects: 180
Study 10964269 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor residual spraying with suspension concentrate (SC) formulation
Number of subjects: 180
Study 10964269 — intervention group
Group type: COMPARATOR
Intervention: Unsprayed control
Number of subjects: 180
Study 10964269 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of Anopheles culicifacies and A.stephensi populations
Number of subjects: 180
Study 8829929 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of 1 mg kg‐1 lignocaine 2% to the medial part of the eye after induction of anaesthesia (Group II)
Number of subjects: 56
Study 8829929 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of lignocaine after a 5 min interval (Group III)
Number of subjects: 56
Study 8829929 — intervention group
Group type: COMPARATOR
Intervention: Stimulation of the reflex without lignocaine (Group I)
Number of subjects: 56
Study 1392493 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose Shu‐Xin oral liquid
Number of subjects: 200
Study 1392493 — intervention group
Group type: COMPARATOR
Intervention: Salvia miltiorrhiza tablet
Number of subjects: 200
Study 2414590 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 160 mg
Number of subjects: 0
Study 2414590 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil or Nisoldipine
Number of subjects: 0
Study 2414590 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists (general)
Number of subjects: 0
Study 31093980 — intervention group
Group type: EXPERIMENTAL
Intervention: hATTR amyloidosis
Number of subjects: 0
Study 31093980 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes
Number of subjects: 0
Study 31093980 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 0
Study 31093980 — intervention group
Group type: COMPARATOR
Intervention: Chronic diseases
Number of subjects: 0
Study 28229570 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional linear periodized resistance training program (EX group, N=10)
Number of subjects: 18
Study 28229570 — intervention group
Group type: COMPARATOR
Intervention: No resistance training (C group, N=8)
Number of subjects: 18
Study 27346728 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 10 mg tablet
Number of subjects: 25
Study 27346728 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 75 mg tablet
Number of subjects: 25
Study 27346728 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 100 mg tablet
Number of subjects: 25
Study 27346728 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 100 mg intravenous bolus
Number of subjects: 25
Study 27346728 — intervention group
Group type: COMPARATOR
Intervention: Brivaracetam 50 mg tablet
Number of subjects: 25
Study 25891548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose PDA-001 (150×10(6) cells)
Number of subjects: 16
Study 25891548 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose PDA-001 (600×10(6) cells)
Number of subjects: 16
Study 25891548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 22198469 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 416
Study 22198469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 20727735 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC+P (Epirubicin, Cisplatin, Capecitabine + Pravastatin 40 mg once daily)
Number of subjects: 30
Study 20727735 — intervention group
Group type: COMPARATOR
Intervention: ECC (Epirubicin, Cisplatin, Capecitabine)
Number of subjects: 30
Study 20727735 — intervention group
Group type: COMPARATOR
Intervention: ECC
Number of subjects: 30
Study 20727735 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC+P
Number of subjects: 30
Study 18830672 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-coping model
Number of subjects: 121
Study 16036099 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g daily
Number of subjects: 0
Study 16036099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12075212 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-appointment group (n = 39)
Number of subjects: 72
Study 12075212 — intervention group
Group type: COMPARATOR
Intervention: 2-appointment group (n = 33)
Number of subjects: 72
Study 10353498 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 138
Study 10353498 — intervention group
Group type: COMPARATOR
Intervention: Low-force mimic (LFM) maneuver
Number of subjects: 138
Study 7497761 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 12
Study 8461542 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus calcitriol
Number of subjects: 103
Study 8461542 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus calcitriol and nasal salmon calcitonin
Number of subjects: 103
Study 8461542 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation alone
Number of subjects: 103
Study 8461542 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol alone
Number of subjects: 103
Study 8461542 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol with nasal calcitonin
Number of subjects: 103
Study 2945717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 30 micrograms
Number of subjects: 30
Study 2945717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 50 micrograms
Number of subjects: 30
Study 2945717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 75 micrograms
Number of subjects: 30
Study 2945717 — intervention group
Group type: COMPARATOR
Intervention: Control (no sufentanil)
Number of subjects: 30
Study 31734798 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Management Service (MMS)
Number of subjects: 129
Study 31734798 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 129
Study 30146136 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 106
Study 30146136 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental reading task
Number of subjects: 106
Study 30146136 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 106
Study 26394882 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium (18 μg once daily) + budesonide/formoterol (160/4.5 μg 2 inhalations twice daily)
Number of subjects: 578
Study 26394882 — intervention group
Group type: COMPARATOR
Intervention: tiotropium alone (18 μg once daily)
Number of subjects: 578
Study 23954497 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-Training (24 nurse-coached exercise sessions)
Number of subjects: 3
Study 23954497 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-Exposure (4 exercise sessions)
Number of subjects: 3
Study 23954497 — intervention group
Group type: COMPARATOR
Intervention: DM (home-walking program)
Number of subjects: 3
Study 22521199 — intervention group
Group type: EXPERIMENTAL
Intervention: Push method
Number of subjects: 59
Study 22521199 — intervention group
Group type: COMPARATOR
Intervention: Pull method
Number of subjects: 59
Study 20816149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 301
Study 20816149 — intervention group
Group type: COMPARATOR
Intervention: No cerclage
Number of subjects: 301
Study 20816149 — intervention group
Group type: EXPERIMENTAL
Intervention: U-shaped funnel
Number of subjects: 301
Study 20816149 — intervention group
Group type: EXPERIMENTAL
Intervention: V-shaped funnel
Number of subjects: 301
Study 18485132 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide prolonged release (PR) 5 mg/day (uptitration to 10 mg/day if no response at 4 or 8 weeks)
Number of subjects: 442
Study 18485132 — intervention group
Group type: COMPARATOR
Intervention: Torasemide immediate release (IR) 5 mg/day (uptitration to 10 mg/day if no response at 4 or 8 weeks)
Number of subjects: 442
Study 18485132 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide prolonged release (PR)
Number of subjects: 442
Study 18485132 — intervention group
Group type: COMPARATOR
Intervention: Torasemide immediate release (IR)
Number of subjects: 442
Study 16181001 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg budesonide inhaled from a Respimat Soft Mist Inhaler (Respimat SMI)
Number of subjects: 14
Study 16181001 — intervention group
Group type: COMPARATOR
Intervention: 200 microg budesonide inhaled from a Turbuhaler dry powder inhaler (Turbuhaler DPI) with fast inhaled flow rate
Number of subjects: 14
Study 16181001 — intervention group
Group type: COMPARATOR
Intervention: 200 microg budesonide inhaled from a Turbuhaler dry powder inhaler (Turbuhaler DPI) with slow inhaled flow rate
Number of subjects: 14
Study 16181001 — intervention group
Group type: COMPARATOR
Intervention: 250 microg beclomethasone dipropionate inhaled from a pressurized metered dose inhaler (Becloforte pMDI)
Number of subjects: 14
Study 12774138 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerine ointment (NGO) applied 10 minutes prior to heelstick
Number of subjects: 50
Study 12774138 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment applied 10 minutes prior to heelstick
Number of subjects: 50
Study 12774138 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerine ointment (NGO)
Number of subjects: 50
Study 12774138 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 50
Study 9658746 — intervention group
Group type: EXPERIMENTAL
Intervention: High school baseball players
Number of subjects: 20
Study 9658746 — intervention group
Group type: COMPARATOR
Intervention: Students without baseball experience
Number of subjects: 20
Study 7982419 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release, prostacyclin-sparing aspirin 75 mg daily plus anticoagulation (intravenous heparin followed by warfarin)
Number of subjects: 144
Study 7982419 — intervention group
Group type: COMPARATOR
Intervention: Conventional aspirin 75 mg daily plus anticoagulation (intravenous heparin followed by warfarin)
Number of subjects: 144
Study 3338726 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental residential treatment program
Number of subjects: 49
Study 3338726 — intervention group
Group type: COMPARATOR
Intervention: Standard postdischarge care
Number of subjects: 49
Study 5762643 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated rubella vaccines
Number of subjects: 54
Study 31991136 — intervention group
Group type: EXPERIMENTAL
Intervention: Valiant Captivia endograft for blunt thoracic aortic injury
Number of subjects: 50
Study 29133007 — intervention group
Group type: COMPARATOR
Intervention: PFD (Posterior Fossa Decompression)
Number of subjects: 90
Study 29133007 — intervention group
Group type: EXPERIMENTAL
Intervention: PFDD (Posterior Fossa Decompression with Duraplasty)
Number of subjects: 90
Study 28419368 — intervention group
Group type: EXPERIMENTAL
Intervention: TT-genotype patients (HIV-uninfected)
Number of subjects: 764
Study 28419368 — intervention group
Group type: COMPARATOR
Intervention: HIV infection
Number of subjects: 764
Study 28419368 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CSF leukocytes and cytokine concentrations
Number of subjects: 764
Study 28419368 — intervention group
Group type: EXPERIMENTAL
Intervention: High CSF proinflammatory cytokine concentrations (HIV-uninfected, TT-genotype patients)
Number of subjects: 764
Study 26603604 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Health Programme (PHP)
Number of subjects: 17
Study 23981507 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based coaching program with education, motivation, exercise guidance, daily SMS reminders, weekly feedback, and active monitoring by general practitioners.
Number of subjects: 186
Study 23981507 — intervention group
Group type: COMPARATOR
Intervention: Usual care and advice from practitioners without the web-based coaching program.
Number of subjects: 186
Study 23981507 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based coaching program
Number of subjects: 186
Study 21346383 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative CRT (45 Gy with chemotherapy)
Number of subjects: 295
Study 21346383 — intervention group
Group type: COMPARATOR
Intervention: Postoperative CRT (45‐51 Gy with chemotherapy)
Number of subjects: 295
Study 18782482 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycaemic index breakfast cereal meal
Number of subjects: 0
Study 18782482 — intervention group
Group type: COMPARATOR
Intervention: Low glycaemic index breakfast cereal meal
Number of subjects: 0
Study 16597076 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclate 400 microg/d
Number of subjects: 15
Study 16597076 — intervention group
Group type: EXPERIMENTAL
Intervention: Qvar 400 microg/d
Number of subjects: 15
Study 16597076 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclate and Qvar at higher doses
Number of subjects: 15
Study 12569265 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT (25 mg once daily for 9 days)
Number of subjects: 8
Study 12569265 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT + LOS (50 mg twice daily for 9 days)
Number of subjects: 8
Study 12569265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11050587 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel plus UVB phototherapy
Number of subjects: 0
Study 11050587 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel plus UVB phototherapy
Number of subjects: 0
Study 11050587 — intervention group
Group type: COMPARATOR
Intervention: UVB phototherapy alone
Number of subjects: 0
Study 9316508 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR stent implantation
Number of subjects: 255
Study 8492925 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide
Number of subjects: 25
Study 8492925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3028545 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven eggs a week
Number of subjects: 168
Study 3028545 — intervention group
Group type: COMPARATOR
Intervention: Two eggs a week
Number of subjects: 168
Study 30281025 — intervention group
Group type: EXPERIMENTAL
Intervention: F/TAF
Number of subjects: 30
Study 30281025 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 30
Study 30281025 — intervention group
Group type: EXPERIMENTAL
Intervention: R/F/TAF
Number of subjects: 30
Study 27252432 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20 (6 mL)
Number of subjects: 99
Study 27252432 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (1 mL of 40-mg + 5 mL of 1% lidocaine with epinephrine)
Number of subjects: 99
Study 25708913 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus targeting 3-8 ng/ml with reduced-exposure cyclosporine (CsA)
Number of subjects: 833
Study 25708913 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus targeting 6-12 ng/ml with reduced-exposure cyclosporine (CsA)
Number of subjects: 833
Study 25708913 — intervention group
Group type: COMPARATOR
Intervention: mycophenolic acid (MPA) with standard-exposure CsA
Number of subjects: 833
Study 23739514 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (60 mg/kg/day for one year)
Number of subjects: 76
Study 20687400 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg/day) administered for 8 to 12 weeks before and during ovarian stimulation
Number of subjects: 232
Study 20687400 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg/day)
Number of subjects: 232
Study 20687400 — intervention group
Group type: COMPARATOR
Intervention: No metformin
Number of subjects: 232
Study 18752932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 409
Study 18752932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 409
Study 18752932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 16632133 — intervention group
Group type: EXPERIMENTAL
Intervention: Print intervention
Number of subjects: 52
Study 16632133 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-plus-telephone intervention
Number of subjects: 52
Study 16632133 — intervention group
Group type: COMPARATOR
Intervention: Baron-Kenny method
Number of subjects: 52
Study 16632133 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 52
Study 12830193 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient information leaflet
Number of subjects: 949
Study 10376164 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical interview by a physician
Number of subjects: 499
Study 10376164 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial occurrence of CTTH
Number of subjects: 499
Study 10376164 — intervention group
Group type: COMPARATOR
Intervention: Gender of probands
Number of subjects: 499
Study 10376164 — intervention group
Group type: COMPARATOR
Intervention: Familial risk of CTTH
Number of subjects: 499
Study 8656661 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg as monotherapy
Number of subjects: 18
Study 8656661 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg plus hydrochlorothiazide (HCTZ 12.5 mg)
Number of subjects: 18
Study 8656661 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ 12.5 mg) alone
Number of subjects: 18
Study 1801883 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐IFN + 5‐Fluorouracil (5‐FU)
Number of subjects: 12
Study 1801883 — intervention group
Group type: COMPARATOR
Intervention: 5‐Fluorouracil (5‐FU) alone
Number of subjects: 12
Study 6127964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral low-dose combination of theophylline (280 mg) and terbutaline (2.5 mg)
Number of subjects: 8
Study 6127964 — intervention group
Group type: COMPARATOR
Intervention: High oral dose of terbutaline (5 mg)
Number of subjects: 8
Study 6127964 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of beta 2-adrenostimulant (1.25 mg terbutaline sulphate)
Number of subjects: 8
Study 31842828 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity supervision PrAISED intervention
Number of subjects: 60
Study 31842828 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity supervision PrAISED intervention
Number of subjects: 60
Study 31842828 — intervention group
Group type: COMPARATOR
Intervention: Brief falls prevention assessment and advice (control)
Number of subjects: 60
Study 31842828 — intervention group
Group type: EXPERIMENTAL
Intervention: PrAISED intervention (both high and moderate supervision)
Number of subjects: 60
Study 31842828 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary efficacy outcome - Disability Assessment for Dementia (DAD)
Number of subjects: 60
Study 31842828 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes - physical activity, quality of life, mood, cognition, strength, balance, rate of falls, frailty, and carer strain
Number of subjects: 60
Study 30049464 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week mHealth intervention (patient education, smartphones, physical activity trackers)
Number of subjects: 20
Study 30049464 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20